期刊文献+

玻璃体切除术治疗增生性糖尿病视网膜病变110例临床疗效分析 被引量:6

Clinical analysis of therapeutic effect in treatment of 110 cases of proliferative diabetic retinopathy by vitrectomy
原文传递
导出
摘要 目的分析及比较玻璃体切除术治疗不同分期增生性糖尿病视网膜病变(PDR)的疗效。方法对PDR110例(120眼)行玻璃体切除术,其中Ⅳ期、V期及Ⅵ期分别为42例(44眼)、48例(52眼)、20例(24眼),术后平均随访6—12个月,比较随访末各期患者视功能改善率及显效率。结果Ⅳ期、V期及Ⅵ期视功能改善率分别为88.6%、73.1%及54.2%,(x^2=7.163,P=0.026);显效率分别为93.2%、53.9%及37.5%。(x^2=7.407,P=0.023)。结论玻璃体切除术是治疗增生性糖尿病视网膜病变的有效方法,病变越早手术效果越显著。 Objective To analyze and compare the effect of vitrectomy on different stages of prolif- erative diabetic retinopathy (PDR). Methods Vitrectomy was undergone in 110 cases (120 eyes) of PDR. Phase IV, V and V[ of PDR were in 42 cases (44 eyes) , 48 case (52 eyes) and 20 case(24 eyes). The improvement rate and effective rate of visual function in every stages were compared after follow-up for 6 - 12 months. Results In phase IV, V and VI of PDR, improvement rates of the visual function were 88.6%, 73.1% and 54.2% (X2 =7. 163, P =0. 026) ; the effective rates were 93.2% , 53.9% and 37.5% (X2 = 7. 407, P = 0. 023). Conclusion Vitrectomy is the effective method for proliferative diabet- ic retinopathy. The earlier vitrectomy is performed, the effect is more significant.
出处 《中华眼外伤职业眼病杂志》 2013年第1期59-61,共3页 Chinese Journal of Ocular Trauma and Occupational Eye Disease
关键词 玻璃体切除术 糖尿病视网膜病变 增生性 疗效 Vitrectomy Diabetic retinopathy, proliferative Effect
作者简介 通讯作者:张招德,Email:Zhangzhaode1973@163.com
  • 相关文献

参考文献10

二级参考文献45

共引文献151

同被引文献42

  • 1李彤,杜玲珍.新生血管性青光眼治疗术式及疗效分析[J].临床医药实践,2005,14(3):192-193. 被引量:2
  • 2Kempen JH,Colmain BJ,Leske MC,et al.Eye Diseases Prevenlence Research Group.The prevenlence of diabetic retinopathy among adults in the untied states[J].Amh Ophthalmol,2004,122:552-563.
  • 3Hershberger VS, Augsburger JJ, Hutchins RK, et al. Fibrovascar ingrowth at sclerotomy sites in vitrectomized diabetic eyes with recurrent vitreous hemorrhage: ultrasound biota icroseopy findings[J], Ophthalmology, 2004, 111:1215-1221.
  • 4Zein WM, Noureddin BN, Jurdi FA, et al. Panretinal photocoag- ulation and intravitreal triamcinolone acetonide for the management of proliferative diabetic retinopathy with macular edema[ J]. Reti- na, 2006, 26(2) : 137-142.
  • 53iang YR, Liang XY, Li XX, et al. Analysis of the clinical effica- cy of intravitreal bevacizumab in the treatment of iris neovascular- ization caused by proliferative diabetic retinopathy[ J]. Acta Oph- thalmologica, 2009, 87 (7) : 736-740.
  • 6Aldebasi YH, Rahmani AH, Khan AA. The effect of vascular en- dothelial growth factor in the progression of bladder cancer and dia- beticretinopathy[J]. Int J Clin Exp Med, 2013, 6(4): 239- 251.
  • 7Lee P. Ocular neovascularization: an epidemiologic review [ J ]. Surv Ophthalmol, 1998, 43 (3) : 245-269.
  • 8Wakabayashi T, Oshima Y, Sakaguchi H, et al. Intravitreal bev- acizumab to treat iris neovascularization and neovascular glaucoma secondary to ischemic retinal diseases in 41 consecutive cases[ J]. Ophthalmology, 2008, 115 (9) : 1571-1580.
  • 9Rosenfeld PJ, Brown DM, Heier JS, et al. Ranibizumab for neo- vascular age-related macular degeneration [ J ]. N Engl J Med, 2006, 355(14) : 1419-1431.
  • 10Liike J, Nassar K, Ltike M, et al. Ranibizumab as adjuvant in the treatment of rubeosis iridis and neovascular glaucoma-results from a prospective interventional case series [ J ]. Graefes Arch Clin Exp Ophthalmol, 2013, 251 (10) : 2403-2413.

引证文献6

二级引证文献26

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部